Risk factors

Heavy reliance on manufacturing in China with 76.6 percent of purchases sourced there in 2024. Significant exposure to pending acquisition risks regarding Kurt Geiger. High dependence on key personnel, notably Founder and Creative Chief Steven Madden.

Underwriting accuracy, distribution dependence on retail agents and brokers, and reserve adequacy dominate Skyward Specialty Insurance Group's risk profile.

NuScale faces concentration risks from reliant commercial partners like RoPower, Fluor, and ENTRA1. The company has no commercial customer contracts yet, significant ongoing losses, and relies on NRC design approvals for its 77 MWe NPM. U.S. tax incentives like the Inflation Reduction Act and DOE cost-sharing awards are critical to ongoing operations.

Syndax relies heavily on the commercial success of newly approved drugs Revuforj and Niktimvo.

Stoneridge relies heavily on top commercial vehicle manufacturers, with PACCAR, Traton, and Volvo representing 42% of 2024 net sales. The company carries $201.6 million in Credit Facility debt with restrictive negative covenants. International operations drive 51% of net sales, exposing the business to foreign currency and tariff risks.

Simpson's business is heavily tied to U.S. housing starts, residential remodeling, and steel raw material price volatility. International sales, software integration, and reliance on key manufacturing facilities in China and domestic third-party logistics drive significant operational risks.

Credit risk and commercial loan concentration dominate S&T Bancorp's risk profile. Geographic market restriction amplifies vulnerability to local economic downturns. Regulatory, interest rate, and liquidity pressures heavily impact banking operations.

The company relies heavily on commercial real estate and loan portfolios concentrated in California. Operations face substantial cybersecurity threats, technological disruption risks, and strict regulatory oversight. Financial results depend strongly on interest rate movements and liquidity management.

ThredUp faces distinct risks in growing its secondhand marketplace by attracting quality items from individual sellers and retaining buyers.

TG Therapeutics relies heavily on the commercial success of its single marketed product, BRIUMVI, for multiple sclerosis.

Tiptree faces significant concentration and execution risks centered around its primary insurance subsidiary Fortegra, active acquisitions, and investment liquidity. Operations are heavily exposed to regulatory capital requirements, claims reserve accuracy, and competitive financial markets. Third-party vendor dependencies and technological vulnerabilities also dominate the risk profile.

UFP Technologies faces risks primarily dominated by raw material shortages, FDA and healthcare regulations, international expansion liabilities, and credit facility covenants.